 |
|
The Effects of Transtympanic Micropressure Treatment in People With Unilateral Ménière's Disease
George A. Gates, MD;
J. Douglas Green, Jr, MD;
Debara L. Tucci, MD;
Steven A. Telian, MD
Arch Otolaryngol Head Neck Surg. 2004;130:718-725.
Objective To evaluate the efficacy of a portable low-intensity alternating pressure generator, the Meniett device, in controlling the symptoms of Ménière's disease.
Design A randomized, placebo-controlled, double-blind, multicenter clinical trial of 4 months' duration.
Setting Four study sites: 3 academic medical centers and 1 private practice.
Patients Sixty-seven people aged 33 to 71 years with established, active, unilateral cochleovestibular Ménière's disease randomly assigned to a treatment or control group. Five cases were excluded (2 dropouts, 3 protocol violations), leaving 62 evaluable cases.
Intervention The Meniett device was self-administered 3 times daily. The placebo Meniett device was identical but exerted no pressure. All participants had a tympanostomy tube inserted in the affected ear.
Main Outcome Measures Participants rated vertigo and activity each day on a symptom report card. Hearing tests, electrocochleography, and questionnaires were completed at baseline, 2 months, and 4 months.
Results The treatment group experienced significantly less severe vertigo, fewer days with definitive vertigo, and fewer days lost from work (sick days) during the follow-up period than did the control group. Hearing and electrocochleographic results did not differ between the groups. Outcomes did not differ by age, gender, laterality, or duration of symptoms. Outcomes were affected by vestibular loss and baseline level of vertigo. The tympanostomy tube had no short-term effect on vertigo symptoms. There were no complications from using the Meniett device.
Conclusion The Meniett device is a minimally invasive, safe, and efficacious intermediate treatment for people with substantial vertigo uncontrolled by medical therapy.
From the Department of Otolaryngology–Head and Neck Surgery, University of Washington School of Medicine, Seattle (Dr Gates); Jacksonville Hearing and Balance Institute, Jacksonville, Fla (Dr Green); Division of Otolaryngology–Head and Neck Surgery, Duke University, Durham, NC (Dr Tucci); and Department of Otolaryngology–Head and Neck Surgery, University of Michigan Medical Center, Ann Arbor (Dr Telian). Dr Gates served as a paid consultant to Medtronic Xomed at a scientific retreat in 2002.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Meniett Clinical Trial: Long-term Follow-up
Gates et al.
Arch Otolaryngol Head Neck Surg 2006;132:1311-1316.
ABSTRACT
| FULL TEXT
Validation of the Meniere's Disease Patient-Oriented Symptom-Severity Index
Gates and Verrall
Arch Otolaryngol Head Neck Surg 2005;131:863-867.
ABSTRACT
| FULL TEXT
|
